Mission and strategy
To provide international biotech and pharmaceutical companies with novel patented antimicrobial and anticancer drugs, identified and characterized from screening of micoorganisms isolated from unique Norwegian marine biobanks.
Through a tight collaboration with its strategic partners, MarBiLeads uses its access to “state-of-the-art” high throughput screening (HTS) equipment, targeted screening and selection technology, experienced expertise in bioprocess development, analysis and molecular structure elucidation of active substances and in vitro and in vivo analysis of compounds, to identify and document unique novel drug leads sold to pharma players in a worldwide market through an established network of agents and representatives. Screening vs multi-drug-resistant (MDR) bacteria (Gram - and Gram +), fungi and a selected spectrum of cancer cell lines are prioritized.
MarBiLeads also invites partners to engage in joint venture projects for the further development of hits and leads compounds of the MarBiLeads pipeline.